Intravenous Solutions Market Size, Share & Trends Analysis Report By Product (TPN, PPN), By Nutrients (Vitamins & Minerals, Single-dose Amino Acids), And By Region (EU, APAC, North America), Segment Forecasts, 2022 - 2030

Report Overview

The global intravenous solutions market size was valued at USD 11.1 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 8.0% over the forecast period. This is due to a rise in natality rate, an increasing geriatric population, a growing prevalence of cancer, and a rise in the prevalence of malnutrition. The COVID-19 pandemic has significantly increased the production of intravenous (IV) solutions. In the ongoing fight against COVID-19, Intensive Care Units (ICUs) are filled with patients infected by COVID-19. The demand for intravenous injections has increased during the pandemic.

Also, the new coronavirus strains have been reported in various parts of the world leading to more people suffering from the virus. As a result, an increase in the number of hospital admissions is also witnessed. Many patients, particularly the elderly and patients with severe lung infections, are put on ventilators for critical care. In such cases, to maintain adequate nutrition, intravenous solutions are constantly provided to such patients. Furthermore, the WHO recommends that patients with COVID-19 having severe respiratory infections should be treated with intravenous fluids. As a result, the demand for IV solutions is projected to increase significantly, particularly during the pandemic.

In addition, breakthroughs in surgical operations and therapies have enhanced life expectancy, resulting in a significant demand for modern medical care. IV nutrition is a crucial aspect of any treatment to help patients meet their nutritional needs and recover faster. When patients are unable to accept nutritional solutions administered by the enteral or oral routes, the Total Parenteral Nutrition (TPN) approach is used. The regulations for the production of large and small volume parenteral utilized in TPN are outlined in FDA Code of Federal Relations Section 201.323.

The increasing prevalence of chronic conditions, such as cancer, boosts the demand for parenteral nutrition across the country. Parenteral nutrition provides vital nutrients that help in maintaining the strength, energy, and hydration of patients suffering from chronic diseases. According to the statistics published by the WHO, approximately 10 million deaths are recorded in 2020 from cancer. Moreover, a 70.0% increase in cancer cases is anticipated over the next couple of decades. The increasing prevalence of cancer is expected to aid in the growth of the market.

Product Insights

The total parenteral nutrition (TPN) segment held the largest revenue share of 66.0% in 2021. This segment is also anticipated to register the fastest CAGR during the forecast year. This is due to the rise in gastrointestinal diseases, such as Ulcerative Colitis (UC) and Crohn’s Disease (CD), in which, patients are unable to absorb essential nutrients and thus, these essential nutrients are delivered through an intravenous route. The growth can also be attributed to a rise in the geriatric population, where the patients require feeding essential nutritional products through intravenous routes.

Based on products, the market has been segmented into total parenteral nutrition and peripheral parenteral nutrition. Peripheral parental nutrition accounted for a steady CAGR during the forecast year. The peripheral parental nutrition method is used when patients cannot ingest an adequate amount of food but can tolerate some amount of oral feeding. It is administered through a hep-lock, also called a peripheral intravenous line, and is supplemented for a short duration, and its peripheral access is relatively easy to establish. The main driver of this segment is the rise in malnutrition across the world population, which requires a sufficient amount of essential nutrients to maintain health.

Nutrients Insights

Based on nutrients, the global market has been further categorized into carbohydrates, single-dose amino acid solution, vitamins & minerals (salt and electrolyte), parenteral lipid emulsion, and others. The single-dose amino acid solution segment held the largest revenue share of 31.5% in 2021. The growth characteristics of this market are that when a patient’s metabolic requirements for protein are considerably augmented due to extensive burns, gastrointestinal absorption of protein is damaged, and the alimentary tract can’t be used in such situations, a single-dose amino acid solution is given to the patient.

Also, single-dose amino acids in combination with vitamins, dextrose, and trace elements are administered to undernourished individuals. The vitamins & minerals (salt and electrolyte) segment is estimated to register the fastest CAGR during the forecast period. This is due to malnutrition as people suffering from this usually have a mineral deficiency, which leads to weak bones, immune systems, and fatigue.  It is also used for the treatment of various diseases, such as beriberi, anemia, chronic mental conditions, and pellagra. Based on nutrients, the market has been segmented into carbohydrates, vitamins & minerals, single-dose amino acids, parenteral lipid emulsion, and others. The others segment includes iron, cobalt (in the form of vitamin B12), zinc, and iodine.

Regional Insights

Based on geographies, the global market has been categorized into North America, Asia Pacific, Middle East & Africa, Latin America, and Europe. North America dominated the global market in 2021 and accounted for the maximum share of more than 40.7% of the overall revenue in the same year. This is due to a rise in the geriatric population that leads to increased demand for intravenous solutions, the increasing prevalence of chronic diseases, and the industry’s expansion to fulfill the rising demands due to the flu and coronavirus pandemic. The Asia-Pacific region is anticipated to register the fastest CAGR during the forecast period.

The high growth of this region can be attributed to the presence of high expenditure by public as well as private entities in the research sector along with technological advancements and the increasing number of collaborations between various stakeholders, including the medical fraternity, universities, and others. In addition, the increasing prevalence of chronic diseases due to unhealthy food consumption tendencies and the rising demand for cost-effective care treatment are among the key factors that are expected to propel the market growth in the Asia Pacific region.

Key Companies & Market Share Insights

The players are continuously expanding their facilities, are engaging in collaboration & acquisition of companies, and are also involved in new product development. These are key strategic initiatives that are influencing the industry dynamics. For instance, in January 2022, ICU Medical acquired a subsidiary of Smiths Group plc that is Smiths Medical. This acquisition will combine the ambulatory infusion devices, syringe, vascular access, and vital care products of Smiths Medical into the existing infusion therapy system of ICU Medical and create an estimated pro forma revenue of approximately USD 2.5 billion. Some of the prominent players in the global intravenous solutions market include:

• Fresenius Kabi AG

• Pfizer, Inc.

• Otsuka Pharmaceutical Co., Ltd.

• Baxter

• B. Braun Melsungen AG

• Vifor Pharma Management Ltd.

• JW Life Science

• Amanta Healthcare

• ICU Medical Inc.

• Grifols, S.A.

Intravenous Solutions Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global intravenous solutions market report based on product, nutrients, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Total Parenteral Nutrition

  • Peripheral Parenteral Nutrition

• Nutrients Outlook (Revenue, USD Million, 2018 - 2030)

  • Carbohydrates

  • Vitamins and Minerals

  • Single Dose Amino Acids

  • Parenteral Lipid Emulsion

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Russia

    • Switzerland

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

  • Middle East & Africa

    • South Africa